Monday 27 June 2016

CSIR launches India’s first anti diabetic ayurvedic drug BGR -34



The Council for Scientific and Industrial Research (CSIR) has launched BGR-34, an anti-diabetic ayurvedic drug designed for type 2 Diabetes mellitus. The anti-diabetic ayurvedic drug BGR-34 has been jointly developedby National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP). About BGR-34 BGR-34 works by controlling blood sugar and
limiting the harmful effects and toxicity of other drugs. It contains 34 identified active phyto-constitutes from herbal resources. It has been economically priced at 5 rupees per tablet as compared to latest DPP4 inhibitors globally. About Council of Scientific and Industrial Research (CSIR) CSIR is an autonomous body and the largest research and development (R&D) organisation in India. It was established in 1942. It operates as an autonomous body registered under the Registration of Societies Act of 1860. It is mainly funded by the Union Ministry of Science and Technology. CSIR’s R&D activities include aerospace engineering, ocean sciences, structural engineering, metallurgy, life sciences, chemicals, mining, food, petroleum, leather, and environment.

No comments:

Post a Comment